Medicare Will Not Cover GLP-1 Drugs for Weight Loss
Wegovy; Zepbound Credit - Steve Christo—Corbis/Getty Images; Shelby Knowles—Bloomberg/Getty Images
The Centers for Medicare and Medicaid Services recently announced—without explanation—that it would not proceed with a proposal initiated by the Biden Administration to cover weight-loss drugs like Wegovy and Zepbound for its beneficiaries.
Medicare and Medicaid recipients can be reimbursed for the medications to treat diabetes, but currently the anti-obesity versions of these drugs will not be covered. As an obesity treatment, Wegovy, made by Novo Nordisk, comes with a slightly higher dose for treating obesity than doses for diabetes; the medication is otherwise the same. For Zepbound, developed by Lilly, it's the same drug and administered in the same dose as Mounjaro, which is used to treat diabetes.
The Biden proposal would have included coverage of Wegovy and Zepbound to treat obesity under Medicare Part D for Medicare Advantage.
'While today's announcement was limited, we hope that with the confirmation of the new CMS director, the Trump Administration will move forward to finalize the definition of obesity. It is essential that CMS regulations are aligned with current medical science—and that means recognizing obesity as a serious chronic disease,' a spokesperson from Novo Nordisk said in a statement to TIME.
A Lilly spokesperson said in a statement to TIME that the company 'is disappointed in the MA-Part D rule because it is not the best reading of the statute and impacts patient access to obesity treatments,' referring to the program that allows enrollees to receive coverage of prescription drugs, including through private plans and through Medicare Advantage. 'We will continue to work with the Trump Administration and Congressional leaders to ensure people living with obesity are covered by Medicare and Medicaid and are no longer left behind.'
The decision not to expand coverage to include obesity treatment would mean nearly 7.5 million Medicare and Medicaid recipients won't be reimbursed for the drug to help them lose weight. Government health care financing analysts noted in Sept. 2024 that the high cost of the drugs would result in higher government spending with 'little information on longer-term effects of the drugs.'
However, health experts have raised concerns that denying coverage could lead to additional health costs for insurers, as scientists are discovering that the drugs come with many other health benefits. The drugs have already received additional indications from the U.S. Food and Drug Administration to lower the risk of heart disease and obstructive sleep apnea. And researchers are currently studying them for other benefits as well, including reducing the risk of kidney, liver, and brain diseases like Alzheimer's and addiction.
Contact us at letters@time.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
30 minutes ago
- Miami Herald
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. Don't miss the move: Subscribe to TheStreet's free daily newsletter As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk (NVO) , while Eli Lilly (LLY) makes Zepbound and Mounjaro. Image source:One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's (MCD) and Domino's Pizza (DPZ) . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 yearsMajor restaurant chain quietly closes several locationsIconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. "But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market," said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients. Related: McDonald's analyst grills new stock price target on McCrispy reaction "Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $455.49. Related: Fund-management veteran skips emotion in investment strategy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Axios
2 hours ago
- Axios
Starbucks taps into health trends with protein coffee test
LAS VEGAS — Starbucks is tapping into the growing demand for protein-packed drinks as consumers seek to boost their intake for health and wellness. Why it matters: The world's largest coffee chain unveiled Tuesday that it is testing protein in its cold foam as part of its "Back to Starbucks" plan. CEO Brian Niccol is trying to reverse a decline in foot traffic and sales by returning to its roots. The big picture: Protein is hot and having a moment beyond social media influencers sharing order hacks. Restaurant brands like Dutch Bros Coffee and Smoothie King have added more protein to their products to cater to changing consumer appetites. Eating a high-protein diet is important to maintain muscle for people taking appetite-suppressing injectable treatments like Ozempic and Wegovy, research shows. Nearly 18 million Americans are expected to be taking versions of GLP-1 drugs by 2029, according to investment bank UBS. Zoom in: Niccol told Axios in an interview Tuesday that the protein cold foam being tested is for a number of different consumer groups including 20-year-old males, 50-year-old females and people taking GLP-1s. "I was watching people coming to our stores, they would get three shots of espresso over ice," Niccol said. "And in some cases, they pull their own protein powder out of their bag, or in other cases, they have a protein drink, like a Fair Life and they'd pour that into their drink." "I'm like, well, wait a second, we can make this experience better for them," he said. "The good news is now I think we're right on trend, and we can do it I think arguably better than anybody else." Flashback: Starbucks had protein smoothies in the past and launched its Vivanno shakes in 2008. They were discontinued in 2018. The company also launched a protein drink in the U.K. last year. The intrigue: Starbucks said the protein powder should be able to be added to any of its cold foam flavors. What's next: Starbucks is testing protein cold foam in five locations in the U.S. under its Starting Five model.
Axios
2 hours ago
- Axios
Former, current CDC employees call on RFK Jr. to resign
Current and former employees of Centers for Disease Control and Prevention are calling on Health Secretary Robert F. Kennedy Jr. to resign, warning that job cuts and proposed funding reductions will hurt the agency's ability to protect the public from future health outbreaks. Why it matters: The Atlanta-based CDC has long been the unbiased hub Americans turn to for facts about health topics, including sexually transmitted infections, maternal and infant health and respiratory infections. Driving the news: Carrying a large American flag, dozens of current employees at the facility walked out in protest of the cuts and joined people rallying in support of the department. Tuesday's protest attracted more than 100 people who packed the sidewalk along Clifton Road across from the CDC's headquarters. What they're saying: Sarah Boim, a member of Fired But Fighting, a grassroots group of former CDC employees who were terminated this year, told Axios the organization holds rallies each Tuesday in support of people who still work at the agency. "It's really hard to put into words how horrible this experience has been, not just for us, but it's going to really affect everybody in America," she said. Eric Mintz, another former CDC employee, told Axios proposed cuts to the CDC, National Institutes for Health, Food and Drug Administration and Medicaid will take away resources needed to protect people from illnesses. "It's not waste, it's not abuse, it's not fraud," Mintz said. "It's hard-working people with expertise trying to protect the American citizens." Catch up quick: The Health and Human Services Department in March announced about 2,400 positions would be eliminated from the CDC. HHS has said reducing its workforce from 82,000 to 62,000 full-time employees will cut costs from the agency's nearly $2 trillion budget. On Monday, RFK. Jr. removed all 17 members from the expert panel that makes vaccine policy recommendations to the CDC. He said in a statement the agency is "prioritizing the restoration of public trust above any specific pro- or anti-vaccine agenda." Questions are still being raised on who runs the CDC, as there is no public health official or designated point person leading the agency. State of play: Trump's fiscal year 2026 budget also recommends cutting $3.59 billion from the CDC. The budget, which was approved by the U.S. House, is still lingering in the U.S. Senate. Threat level: Anna Yousaf, an infectious diseases doctor at the CDC's National Center for Immunization and Respiratory Diseases, called Kennedy a "domestic health threat" who has dismantled programs ranging from lead poisoning prevention to maternal and infant health monitoring.
